Genmab Résultats passés
Passé contrôle des critères 2/6
Genmab a connu une croissance annuelle moyenne de ses bénéfices de 18%, tandis que le secteur Biotechs a vu ses bénéfices augmenter de en hausse à 13.3% par an. Les revenus ont augmenté de en hausse à un taux moyen de 23.6% par an. Le rendement des capitaux propres de Genmab est 14.4% et ses marges nettes sont de 21%.
Informations clés
18.05%
Taux de croissance des bénéfices
19.10%
Taux de croissance du BPA
| Biotechs Croissance de l'industrie | 18.72% |
| Taux de croissance des recettes | 23.62% |
| Rendement des fonds propres | 14.45% |
| Marge nette | 21.05% |
| Prochaine mise à jour des résultats | 06 Aug 2026 |
Mises à jour récentes des performances passées
Recent updates
Mise à jour du récit • May 26
GMAB: Late Stage Oncology Readouts Will Support Stronger Margins And Earnings Quality
Genmab's analyst price target has been trimmed slightly to DKK 3,000, as analysts factor in more measured revenue growth expectations, a modestly higher discount rate, and a somewhat richer forward P/E outlook. They are still pointing to solid margin potential and recent bullish rating updates from several firms.Article d’analyse • May 15
There May Be Some Bright Spots In Genmab's (CPH:GMAB) Earnings
The most recent earnings report from Genmab A/S ( CPH:GMAB ) was disappointing for shareholders. While the headline...Article d’analyse • May 11
Analyst Estimates: Here's What Brokers Think Of Genmab A/S (CPH:GMAB) After Its First-Quarter Report
Genmab A/S ( CPH:GMAB ) shareholders are probably feeling a little disappointed, since its shares fell 3.9% to kr.1,642...
Mise à jour du récit • Apr 29
GMAB: 2026 Pipeline Catalysts Will Test Balanced Risk And Opportunity Outlook
Narrative Update on Genmab The updated analyst framework lifts Genmab's fair value estimate from DKK 1,300 to about DKK 1,588. This reflects higher assumed revenue growth and P/E multiples as analysts factor in recent upgrades, resumed coverage and new acquisition driven pipeline contributions.
Mise à jour du récit • Apr 15
GMAB: 2026 Clinical Readouts And AI Use Will Shape Outlook
Genmab's updated analyst price target edges slightly lower to DKK 2,233 from DKK 2,238, as analysts factor in mixed views around Epkinly assumptions, acquisition driven pipeline updates, and a modestly higher future P/E expectation despite broadly constructive long term growth potential. Analyst Commentary Recent research on Genmab reflects a mix of optimism around the expanded pipeline and upcoming catalysts, alongside caution tied to Epkinly assumptions and valuation.Mise à jour du récit • Mar 31
GMAB: 2026 Late Stage Oncology Catalysts Will Support Stronger Margin Profile
Genmab's updated analyst price target now sits at DKK 3,017, a modest reset from DKK 3,060 as analysts factor in higher discount rates, revised long term margin expectations, and recent research that reflects both increased revenue growth assumptions and a lower future P/E multiple. Analyst Commentary Recent Street research around Genmab has centered on how new clinical and portfolio developments filter into valuation, with several bullish analysts updating price targets and investment cases to reflect revised expectations on execution and long term growth potential.Mise à jour du récit • Mar 17
GMAB: 2026 Catalyst Calendar Will Likely Expose Downside Risk Ahead
Analysts have lifted the Genmab fair value estimate from DKK 1,075.93 to DKK 1,300.00, reflecting updated views on revenue growth, profitability and future P/E, following recent price target revisions and renewed coverage across the Street. Analyst Commentary Recent Street research on Genmab points to a mix of optimism and caution, with valuation views reset around updated expectations for key pipeline assets and royalty streams.Mise à jour du récit • Mar 03
GMAB: 2026 Catalyst Events And AI Adoption Will Shape Outlook
Genmab's analyst fair value estimate has moved up from DKK 2,182 to DKK 2,238, as analysts factor in higher long term revenue growth assumptions, a higher future P/E and recent price target revisions around DKK 2,400 to DKK 2,500, even as they temper near term expectations for Epkinly and margins. Analyst Commentary Recent research points to a more nuanced view of Genmab, with several firms adjusting their price targets and models following the latest earnings, product updates and acquisition activity.Mise à jour du récit • Feb 17
GMAB: 2026 Pipeline Readouts And AI Use Will Drive Outlook
Analysts have made a small trim to their blended DKK price target on Genmab, with the model now pointing to roughly DKK 2,182. This reflects updated assumptions around slightly higher discount rates, a modestly different margin outlook and a lower future P/E multiple after recent coverage resets and target hikes from banks like Morgan Stanley, Deutsche Bank and Barclays.Mise à jour du récit • Feb 02
GMAB: Phase 3 Data, AI Adoption And 2026 Readout Will Shape Outlook
Genmab’s analyst fair value estimate has moved modestly higher to DKK 2,188.94. Analysts point to updated assumptions around slightly lower discount rates, adjusted revenue growth and profit margin expectations, and a recalibrated future P/E multiple as the key drivers behind the refreshed price targets.Mise à jour du récit • Jan 19
GMAB: Phase 3 Setback And 2026 Readout Will Shape Market Outlook
Genmab’s analyst price target has been lifted by roughly DKK 100 to reflect updated expectations around slightly higher revenue growth and profit margin assumptions, as analysts point to recent target increases from DKK 2,000 to DKK 2,400 and DKK 2,500 as support for a higher fair value range. Analyst Commentary Recent Street research on Genmab reflects a generally constructive stance, with higher price targets and continued attention on upcoming clinical milestones.Mise à jour du récit • Jan 05
GMAB: Late Stage Oncology Focus Will Drive Stronger Margins And Repricing
Analysts have increased their fair value estimate for Genmab from DKK 2,700 to approximately DKK 3,060, reflecting updated assumptions that combine lower projected revenue growth with higher profit margins and a reduced future P/E multiple. What's in the News Genmab plans to discontinue further clinical development of acasunlimab and to concentrate resources on late stage programs such as EPKINLY (epcoritamab), petosemtamab and rinatabart sesutecan, described as part of its disciplined portfolio and capital allocation framework (Key Developments).Mise à jour du récit • Dec 14
GMAB Merus Deal Will Likely Expose Downside Risk At Current Levels
Analysts have lifted Genmab's fair value estimate from DKK 1,015 to about DKK 1,076, reflecting a series of higher price targets that cite the Merus acquisition's boost to the late stage pipeline and underappreciated royalty revenue upside as key drivers. Analyst Commentary Recent Street research on Genmab remains broadly constructive, with multiple firms lifting price targets and highlighting the strategic merits of the Merus acquisition.Mise à jour du récit • Nov 29
GMAB: Merus Acquisition and Pipeline Depth Will Shape Market Outlook
Genmab's analyst price target has seen a modest decrease of approximately DKK 3.57 to DKK 2,054.66. Analysts are factoring in sustaining growth drivers from recent pipeline acquisitions while adjusting for updates to discount rate and margin assumptions.Mise à jour du récit • Nov 15
GMAB: Future Pipeline Expansion and Merus Acquisition Will Define Performance
Genmab's analyst price target has been raised from approximately DKK 2,017 to DKK 2,058. This reflects analysts' increased confidence in the company's pipeline expansion, notably following the Merus acquisition and upside potential from key assets such as Epkinly.Mise à jour du récit • Nov 01
GMAB: Recent Acquisition Will Drive Pipeline Expansion While Integration Risks Remain
Genmab's fair value estimate has been raised from DKK 2,012.92 to DKK 2,017.35. Analysts highlight the Merus acquisition's positive impact on the late-stage pipeline and renewed confidence in royalty revenue growth opportunities.Mise à jour du récit • Oct 18
Pipeline Progress And International Expansion Will Unlock Market Opportunities
Genmab's analyst fair value target has increased slightly, rising from DKK 2,005 to DKK 2,013. Analysts cite royalty revenue upside and pipeline expansion following recent M&A activity as key drivers for the upward revisions.Mise à jour du récit • Oct 04
Pipeline Progress And International Expansion Will Unlock Market Opportunities
Genmab's analyst price target was raised from approximately $1,942 to $2,005. This reflects increased confidence among analysts in the company's growth outlook and pipeline expansion following recent acquisitions.Article d’analyse • Sep 24
Here's Why We Think Genmab (CPH:GMAB) Might Deserve Your Attention Today
Investors are often guided by the idea of discovering 'the next big thing', even if that means buying 'story stocks...Mise à jour du récit • Sep 04
Pipeline Progress And International Expansion Will Unlock Market Opportunities
Genmab’s consensus price target was unchanged at DKK1942, as strong sales momentum and positive pipeline updates were offset by concerns about rising competition and tempered long-term growth expectations. Analyst Commentary Bullish analysts are raising price targets following stronger-than-expected sales momentum for Genmab's key oncology products.Article d’analyse • Jul 31
Investors Aren't Entirely Convinced By Genmab A/S' (CPH:GMAB) Earnings
When close to half the companies in Denmark have price-to-earnings ratios (or "P/E's") above 16x, you may consider...
Nouveau récit • Nov 11
Decisive Advances And DuoBody Innovation Propel Future Growth In Biotech Frontiers
Genmab's focus on late-stage therapies, particularly EPKINLY, is expected to boost future revenue and growth due to best-in-class technology and market approvals.Ventilation des recettes et des dépenses
Ventilation des recettes et des dépenses
Comment Genmab gagne et dépense de l'argent. Sur la base des derniers bénéfices déclarés, sur une base LTM.
Historique des gains et des recettes
| Date | Recettes | Les revenus | Dépenses G+A | Dépenses de R&D |
|---|---|---|---|---|
| 31 Mar 26 | 3,901 | 821 | 666 | 1,687 |
| 31 Dec 25 | 3,720 | 963 | 626 | 1,606 |
| 30 Sep 25 | 3,846 | 1,583 | 643 | 1,567 |
| 30 Jun 25 | 3,647 | 1,371 | 624 | 1,550 |
| 31 Mar 25 | 3,233 | 1,136 | 550 | 1,438 |
| 31 Dec 24 | 3,121 | 1,133 | 549 | 1,414 |
| 30 Sep 24 | 2,964 | 702 | 519 | 1,349 |
| 30 Jun 24 | 2,743 | 798 | 501 | 1,276 |
| 31 Mar 24 | 2,576 | 791 | 504 | 1,187 |
| 01 Jan 24 | 2,390 | 631 | 478 | 1,107 |
| 30 Sep 23 | 2,389 | 590 | 466 | 1,033 |
| 30 Jun 23 | 2,378 | 680 | 453 | 979 |
| 31 Mar 23 | 2,216 | 757 | 422 | 890 |
| 31 Dec 22 | 2,088 | 785 | 385 | 801 |
| 30 Sep 22 | 1,580 | 745 | 299 | 688 |
| 30 Jun 22 | 1,438 | 558 | 268 | 683 |
| 31 Mar 22 | 1,342 | 354 | 228 | 667 |
| 31 Dec 21 | 1,288 | 452 | 196 | 640 |
| 30 Sep 21 | 1,232 | 448 | 156 | 590 |
| 30 Jun 21 | 1,168 | 401 | 134 | 541 |
| 31 Mar 21 | 1,703 | 880 | 119 | 512 |
| 31 Dec 20 | 1,660 | 781 | 108 | 515 |
| 30 Sep 20 | 1,736 | 889 | 86 | 453 |
| 30 Jun 20 | 1,559 | 853 | 73 | 417 |
| 31 Mar 20 | 837 | 349 | 56 | 378 |
| 31 Dec 19 | 806 | 325 | 51 | 358 |
| 30 Sep 19 | 532 | 223 | 42 | 317 |
| 30 Jun 19 | 487 | 178 | 39 | 291 |
| 31 Mar 19 | 441 | 202 | 36 | 250 |
| 31 Dec 18 | 464 | 226 | 33 | 220 |
| 30 Sep 18 | 437 | 222 | 30 | 191 |
| 30 Jun 18 | 397 | 194 | 28 | 174 |
| 31 Mar 18 | 462 | 213 | 26 | 164 |
| 31 Dec 17 | 381 | 178 | 24 | 137 |
| 30 Sep 17 | 361 | 184 | 21 | 126 |
| 30 Jun 17 | 356 | 208 | 19 | 110 |
| 31 Mar 17 | 272 | 174 | 16 | 101 |
| 31 Dec 16 | 257 | 168 | 14 | 94 |
| 30 Sep 16 | 221 | 111 | 15 | 97 |
| 30 Jun 16 | 205 | 102 | 14 | 90 |
| 31 Mar 16 | 183 | 82 | 14 | 81 |
| 31 Dec 15 | 165 | 111 | 13 | 71 |
| 30 Sep 15 | 116 | 66 | 14 | 66 |
| 30 Jun 15 | 115 | 69 | 14 | 66 |
Des revenus de qualité: GMAB a des bénéfices de haute qualité.
Augmentation de la marge bénéficiaire: Les marges bénéficiaires nettes actuelles de GMAB sont inférieures à celles de l'année dernière GMAB. (21%) sont inférieures à celles de l'année dernière (35.1%).
Analyse des flux de trésorerie disponibles par rapport aux bénéfices
Analyse de la croissance passée des bénéfices
Tendance des revenus: Les bénéfices de GMAB ont augmenté de 18% par an au cours des 5 dernières années.
Accélération de la croissance: GMAB a connu une croissance négative de ses bénéfices au cours de l'année écoulée, elle ne peut donc pas être comparée à sa moyenne sur 5 ans.
Bénéfices par rapport au secteur d'activité: GMAB a enregistré une croissance négative de ses bénéfices ( -27.7% ) au cours de l'année écoulée, ce qui rend difficile la comparaison avec la moyenne du secteur Biotechs ( 21.7% ).
Rendement des fonds propres
ROE élevé: Le retour sur capitaux propres de GMAB ( 14.4% ) est considéré comme faible.
Rendement des actifs
Rendement des capitaux employés
Découvrir des entreprises performantes dans le passé
Analyse de l'entreprise et données financières
| Données | Dernière mise à jour (heure UTC) |
|---|---|
| Analyse de l'entreprise | 2026/05/29 20:40 |
| Cours de l'action en fin de journée | 2026/05/29 00:00 |
| Les revenus | 2026/03/31 |
| Revenus annuels | 2025/12/31 |
Sources de données
Les données utilisées dans notre analyse de l'entreprise proviennent de S&P Global Market Intelligence LLC. Les données suivantes sont utilisées dans notre modèle d'analyse pour générer ce rapport. Les données sont normalisées, ce qui peut entraîner un délai avant que la source ne soit disponible.
| Paquet | Données | Cadre temporel | Exemple de source américaine * |
|---|---|---|---|
| Finances de l'entreprise | 10 ans |
| |
| Estimations consensuelles des analystes | +3 ans |
|
|
| Prix du marché | 30 ans |
| |
| Propriété | 10 ans |
| |
| Gestion | 10 ans |
| |
| Principaux développements | 10 ans |
|
* Exemple pour les titres américains ; pour les titres non américains, des formulaires réglementaires et des sources équivalentes sont utilisés.
Sauf indication contraire, toutes les données financières sont basées sur une période annuelle mais mises à jour trimestriellement. C'est ce qu'on appelle les données des douze derniers mois (TTM) ou des douze derniers mois (LTM). En savoir plus.
Modèle d'analyse et flocon de neige
Les détails du modèle d’analyse utilisé pour générer ce rapport sont disponibles sur notre page Github; nous proposons également des guides expliquant comment utiliser nos rapports et des tutoriels sur Youtube.
Découvrez l'équipe de classe mondiale qui a conçu et construit le modèle d'analyse Simply Wall St.
Indicateurs de l'industrie et du secteur
Nos indicateurs de secteur et de section sont calculés toutes les 6 heures par Simply Wall St. Les détails de notre processus sont disponibles sur Github.
Sources des analystes
Genmab A/S est couverte par 41 analystes. 22 de ces analystes ont soumis les estimations de revenus ou de bénéfices utilisées comme données d'entrée dans notre rapport. Les soumissions des analystes sont mises à jour tout au long de la journée.
| Analyste | Institution |
|---|---|
| James Gordon | Barclays |
| Xue Chen | Barclays |
| Emily Field | Barclays |